Revvity molecular reference standards are available for both germline and somatic variants. In this article we cover why this distinction is important, and what it means for the allele frequencies of variants in these two types of controls.
Functional genomic screening allows for the elucidation of the mechanism of action of exogenous agents which modulate intracellular gene function such as pharmaceutical agents and other compounds. Read about the various considerations, approaches and interpretations when conducting a screen to investigate novel compounds and analyzing the screening data.
With the requirement of thorough in vitro assays and high throughput screening technologies to ensure drug safety and efficacy, make sure you're fully ready for when you submit your IND application by assessing immunogenicity with an MLR assay
In pooled CRISPR drug-gene screens two selection mechanisms can be applied, positive or resistance and negative or sensitivity screening, with each having various considerations and uses
Functional Genomic and Cell Panel Screening can individually provide comprehensive data sets to support therapeutic development, but when utilized in combination they identify novel targets which are cross-validated by independent approaches.
When making a knockout cell line using CRISPR, western blotting is a useful tool to help in the verification of the cell line. However, correct interpretation of results is crucial. Here we summarize the possible fates of a protein after knockout and explore how best to validate a knockout cell line
Learn about how T cell exhaustion poses a significant challenge in immuno-oncology and the way epigenetic mechanisms can help develop strategies for reinvigorating exhausted T cells.
A study where we have employed orthogonal target validation strategies with 3 orthogonal LOF technologies (CRISPRko, CRISPRi, and siRNA) with genes involved in maintenance of the mesenchymal-to-epithelial transition (MET).
Learn about considerations around the development of the Dharmacon™ Edit-R™ CRISPRko algorithm for functional and specific guide RNA
Cell panel screening assays are an essential part of the drug discovery toolbox. However, fully resolving the drug response profiles of slow-acting therapeutics remains challenging with conventional short term assay formats. Elucidation of the effects of these drug candidates, and those that target epigenetic pathways, requires much greater optimization of longer-term assay conditions.